• Nintedanib shows promise for malignant pleural mesothelioma

    4 days ago - By Healio

    CHICAGO - The addition of nintedanib to pemetrexed/cisplatin appeared safe and effective for the treatment of patients with malignant pleural mesothelioma, according to results from the LUME-Meso trial presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.Nintedanib is an intracellular inhibitor that targets multiple tyrosine kinases, including VEGFR 1-3, PDGFR /, FGFR 1-3, Src and Abl.
    Read more ...